Literature DB >> 3674472

The pharmacokinetics of atracurium isomers in vitro and in humans.

D Tsui1, G G Graham, T A Torda.   

Abstract

Atracurium is a mixture of ten isomers. By high-performance liquid chromatography, using acidified methanol as the mobile phase and silica support, it was separated into its three geometrical isomer groups, cis-cis, cis-trans, and trans-trans, which contain three, four, and three isomers, respectively. The clinically available form of atracurium was made up of 58% cis-cis, 36% cis-trans, and 6% trans-trans isomers. In buffered saline, pH 7.4, at 37 degrees C, the half-lives of the three isomer groups were 57.1 +/- 0.9, 59.7 +/- 0.9, and 66.4 +/- 2.7 min, respectively, for the cis-cis, cis-trans, and trans-trans groups. In whole blood, under similar conditions, the three groups showed different behavior. The cis-cis group broke down in a monoexponential manner with a half-life of 23.3 +/- 2.8 min. The cis-trans group showed bi-exponential breakdown with a rapid phase of 2.3 +/- 0.4 min and a slow phase of 22.1 +/- 2.9 min. The trans-trans group decayed rapidly, but, because of the low concentration of this group in the mixture, kinetic parameters could not be obtained. In eight patients, the mean elimination half-life and apparent clearance of the cis-cis group were 20.6 +/- 1.5 min and 5.3 +/- 0.4 ml.kg-1.min-1, respectively. For the cis-trans group, the apparent elimination half-life and clearance were 17.7 +/- 1.8 min and 9.0 +/- 1.0 ml.kg-1.min-1, but these figures require care in interpretation, as this isomer group contains isomers of widely varying rates of decomposition.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3674472     DOI: 10.1097/00000542-198711000-00017

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  A pharmacokinetic-pharmacodynamic model for a muscle relaxant: atracurium.

Authors:  V Nigrovic; J Gaspari; M Banoub
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

4.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

5.  Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation.

Authors:  L S Bluestein; L W Stinson; R L Lennon; S N Quessy; R M Wilson
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

6.  Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.

Authors:  R H Vandenbrom; J M Wierda; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 7.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

8.  Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.

Authors:  V Nigrovic; M Banoub
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

9.  Chirality and anaesthetic drugs: A review and an update.

Authors:  Sukanya Mitra; Puneet Chopra
Journal:  Indian J Anaesth       Date:  2011-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.